Maxgalin 75 Capsule contains Pregabalin 75 mg, an anticonvulsant and neuropathic pain agent primarily used in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. It is also indicated as adjunctive therapy for partial seizures in adults and for the treatment of generalized anxiety disorder. Pregabalin acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby modulating neurotransmitter release and reducing neuronal excitability. Maxgalin 75 Capsule is well-absorbed orally, with peak plasma concentrations achieved within one hour, and it exhibits linear pharmacokinetics. The medication is generally well-tolerated; common adverse effects include dizziness, somnolence, dry mouth, and peripheral edema. Dose adjustments may be necessary in patients with renal impairment. Caution is advised when prescribing to patients with a history of substance abuse or depression. Maxgalin 75 Capsule should be used under medical supervision, with gradual dose titration to minimize side effects. It is contraindicated in patients with known hypersensitivity to pregabalin or any of its excipients. Pregabalin should not be abruptly discontinued to avoid withdrawal symptoms. This medication is a valuable option in the management of neuropathic pain and seizure disorders, improving patient quality of life when used appropriately.